Public relations company Padilla announced on Thursday that three in five US employees working without a COVID-19 vaccination policy expect their companies to create one and would not feel comfortable returning to work unless at least 50% of all employees are vaccinated.
This survey is based a new study commissioned by Padilla and conducted by its research division, SMS Research Advisors. SMS Research Advisors surveyed 1,026 people employed in the workforce of varying ages, positions/levels and industries in January 2021, with 8.4% of survey respondents working in health care. About 85% of employees supported the approach of COVID-19 vaccine policy.
Almost half of employees working for companies with 1,000 or fewer co-workers, want 75% or more of their co-workers vaccinated before they return to the workplace. In general, organizations are not requiring their employees to receive a COVID-19 vaccine, added Padilla.
The most common opposition to a mandatory workplace vaccination policy comes from employees who want to receive a vaccine, but do not think their employer should require it and those who oppose the vaccine altogether and do not want their employer to require it. The vaccinations should be mandatory for any job that requires human-to-human interaction, concluded Padilla.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA